» Articles » PMID: 32873154

Phenotypes from Cell-free DNA

Overview
Journal Open Biol
Date 2020 Sep 3
PMID 32873154
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Cell-free DNA (cfDNA) has the potential to enable non-invasive detection of disease states and progression. Beyond its sequence, cfDNA also represents the nucleosomal landscape of cell(s)-of-origin and captures the dynamics of the epigenome. In this review, we highlight the emergence of cfDNA epigenomic methods that assess disease beyond the scope of mutant tumour genotyping. Detection of tumour mutations is the gold standard for sequencing methods in clinical oncology. However, limitations inherent to mutation targeting in cfDNA, and the possibilities of uncovering molecular mechanisms underlying disease, have made epigenomics of cfDNA an exciting alternative. We discuss the epigenomic information revealed by cfDNA, and how epigenomic methods exploit cfDNA to detect and characterize cancer. Future applications of cfDNA epigenomic methods to act complementarily and orthogonally to current clinical practices has the potential to transform cancer management and improve cancer patient outcomes.

Citing Articles

Isolation and Characterization of Cell-Free DNA from Cerebral Organoids.

Silver B, Brooks A, Gerrish K, Tokar E Int J Mol Sci. 2024; 25(10).

PMID: 38791569 PMC: 11121789. DOI: 10.3390/ijms25105522.


Hypobaric hypoxia modulated structural characteristics of circulating cell-free DNA in high-altitude pulmonary edema.

Ali M, Choudhary R, Singh K, Kumari S, Kumar R, Graham B Am J Physiol Lung Cell Mol Physiol. 2024; 326(4):L496-L507.

PMID: 38349115 PMC: 11905808. DOI: 10.1152/ajplung.00245.2023.


The Value of Cell-Free Circulating DNA Profiling in Patients with Skin Diseases.

Ma J, Teng Y, Youming H, Tao X, Fan Y Methods Mol Biol. 2023; 2695:247-262.

PMID: 37450124 DOI: 10.1007/978-1-0716-3346-5_17.


Cell-free DNA as a potential biomarker of differentiation and toxicity in cardiac organoids.

Silver B, Gerrish K, Tokar E Elife. 2023; 12.

PMID: 37261896 PMC: 10287154. DOI: 10.7554/eLife.83532.


Transcription factor-nucleosome dynamics from plasma cfDNA identifies ER-driven states in breast cancer.

Rao S, Han A, Zukowski A, Kopin E, Sartorius C, Kabos P Sci Adv. 2022; 8(34):eabm4358.

PMID: 36001652 PMC: 9401618. DOI: 10.1126/sciadv.abm4358.


References
1.
Mouliere F, Chandrananda D, Piskorz A, Moore E, Morris J, Ahlborn L . Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018; 10(466). PMC: 6483061. DOI: 10.1126/scitranslmed.aat4921. View

2.
Salk J, Loubet-Senear K, Maritschnegg E, Valentine C, Williams L, Higgins J . Ultra-Sensitive TP53 Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue over a Century of Human Lifespan. Cell Rep. 2019; 28(1):132-144.e3. PMC: 6639023. DOI: 10.1016/j.celrep.2019.05.109. View

3.
Kulaeva O, Hsieh F, Studitsky V . RNA polymerase complexes cooperate to relieve the nucleosomal barrier and evict histones. Proc Natl Acad Sci U S A. 2010; 107(25):11325-30. PMC: 2895129. DOI: 10.1073/pnas.1001148107. View

4.
Venkatesh S, Workman J . Histone exchange, chromatin structure and the regulation of transcription. Nat Rev Mol Cell Biol. 2015; 16(3):178-89. DOI: 10.1038/nrm3941. View

5.
Gezer U, Ustek D, Yoruker E, Cakiris A, Abaci N, Leszinski G . Characterization of H3K9me3- and H4K20me3-associated circulating nucleosomal DNA by high-throughput sequencing in colorectal cancer. Tumour Biol. 2012; 34(1):329-36. DOI: 10.1007/s13277-012-0554-5. View